Literature DB >> 10866228

Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG.

C Montavon1, C Toure-Kane, F Liegeois, E Mpoudi, A Bourgeois, L Vergne, J L Perret, A Boumah, E Saman, S Mboup, E Delaporte, M Peeters.   

Abstract

The genetic subtype was identified in gag and env of 219 HIV-1-positive samples collected in different African countries, 44 from Senegal, 55 from Cameroon, 82 from Gabon, and 38 from Djibouti. In total, 20 (9.1%) samples had discordant subtypes between gag and env, 6 of 44 (13.9%) in Senegal, 4 of 55 (7.2%) in Cameroon, 1 of 38 (2.6%) in Djibouti, and 10 of 82 (12.1%) in Gabon. Subtypes A and G were predominantly involved in the recombination events. Phylogenetic tree analysis of gag showed that an important number of the A sequences form a distinct subcluster with the AG-IBNG prototype strain (a complex A/G mosaic virus): 27 of 32 (84.3%) in Senegal, 12 of 17 (70.6%) in Nigeria, 24 of 39 (61.5%) in Cameroon, and 38 of 70 (54.3%) in Gabon. Full-length genome analysis of 3 and additional sequences in pol for 10 such strains confirmed that they have a similar complex A/G mosaic genomic structure. These data suggest that in West Africa, most probably between 60% and 84% of the subtype A viruses are recombinant AG-IBNG viruses. This finding has potential implications on future vaccine, diagnostic, and treatment strategies. The actual and future role of these viruses in the global pandemic must be monitored in all new molecular epidemiologic studies, a discrimination between subtype A and AG-IBNG-like viruses is necessary.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866228     DOI: 10.1097/00126334-200004150-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.

Authors:  Jean-Christophe Plantier; Laurence Vergne; Florence Damond; Souleymane MBoup; Eitel MPoudi-NGole; Laurence Buzelay; Isabelle Farfara; Denys Brand; Martine Peeters; Françoise Brun-Vézinet; Eric Delaporte; Francis Barin
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Characterization of primary isolates of HIV type 1 CRF28_BF, CRF29_BF, and unique BF recombinants circulating in São Paulo, Brazil.

Authors:  Fernando Lucas Melo; Leda Fátima Jamal; Paolo Marinho de Andrade Zanotto
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-16       Impact factor: 2.205

Review 3.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

4.  Identification and characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx recombinant subtypes in Mali, West Africa.

Authors:  Hiromi Imamichi; Ousmane Koita; Djeneba Dabitao; Sounkalo Dao; Mahamadou Ibrah; Dramane Sogoba; Robin L Dewar; Steve C Berg; Min-Kang Jiang; Mark Parta; Janice A Washington; Michael A Polis; H Clifford Lane; Anatole Tounkara
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

5.  Clade A HIV-1 Gag-specific T cell responses are frequent but do not correlate with viral loads in a cohort of treatment-naive HIV-infected individuals living in Guinea-Bissau.

Authors:  Kristoffer Jarlov Jensen; Victor Raúl Gómez Román; Sanne Skov Jensen; Christian Leo-Hansen; Ingrid Karlsson; Terese Lea Katzenstein; Candida Medina Rodrigues; Sanne Jespersen; Christoph Mikkel Janitzek; David da Silva Té; Peter Hayes; Anders Fomsgaard
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

6.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

7.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Development of an env gp41-based heteroduplex mobility assay for rapid human immunodeficiency virus type 1 subtyping.

Authors:  S M Agwale; K E Robbins; L Odama; A Saekhou; C Zeh; A Edubio; O M Njoku; N Sani-Gwarzo; M F Gboun; F Gao; M Reitz; D Hone; T M Folks; D Pieniazek; C Wambebe; M L Kalish
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

9.  Field evaluation of the gag-based heteroduplex mobility assay for genetic subtyping of circulating recombinant forms of human immunodeficiency virus type 1 in Abidjan, Côte d'Ivoire.

Authors:  Souleymane Sawadogo; Christiane Adjé-Touré; Celestin E Bilé; Rene E A Ekpini; Terence Chorba; John N Nkengasong
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Development, evaluation, and validation of an oligonucleotide probe hybridization assay to subtype human immunodeficiency virus type 1 circulating recombinant form CRF02_AG.

Authors:  Harr F Njai; Gert Van der Auwera; Chiambah A Ngong; Leo Heyndrickx; Souleymane Sawadago; Hilton Whittle; Phillipe Nyambi; Robert Colebunders; Guido van der Groen; Wouter Janssens
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.